Lupus & antiphospholipid syndrome
Comprehensive risk assessment for pulmonary manifestations in systemic lupus erythematosus: a large-scale Korean population-based longitudinal study
Main finding · Pulmonary manifestationsResult — go to the resultAdjusted hazard ratio 3.26 95% CI 2.99–3.56Authors' conclusion
Subjects with SLE have an approximately 3.3-fold higher risk of pulmonary manifestations compared with matched controls.
Study context
- Population
- Adults aged ≥20 years, Korean National Health Insurance Service data (2009–2017)mean follow-up 9.3±2.7 years
- Participants
- 6,074 vs 60,740
- Exposure
- Newly diagnosed systemic lupus erythematosus (SLE) vs matched controls without SLE
- SLEn = 6,074
- Matched controlsn = 60,740reference
- Outcome
- Pulmonary manifestations
Methodological detailspopulation-based, longitudinal, matched (1:10) by age and sex
- Population-based
- Longitudinal
- Matched (1:10) by age and sex
Main finding
As reported in the abstract
Adjusted hazard ratio
3.26
95% CI 2.99–3.56
By group
SLEvs Matched controls
aHR 3.26 (95% CI 2.99–3.56)
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Comprehensive risk assessment for pulmonary manifestations in systemic lupus erythematosus: a large-scale Korean population-based longitudinal study. RMD Open. Published 23 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →